Equibles does not estimate personal net worth.
Earlier roles on record: COO at CytomX Therapeutics, Inc. (CTMX) until September 12, 2022. CytomX Therapeutics, Inc. reported in an 8-K filed July 13, 2022 that Amy Peterson was terminated as President and Chief Operating Officer, effective September 12, 2022. The proxy statement of Exelixis, Inc. reports total compensation of $11,146,034 for Amy Peterson in fiscal 2025, including a base salary of $614,496. Disclosed compensation is on record for 7 fiscal years. Amy Peterson has spoken on 2 earnings calls across 1 company, most recently for CytomX Therapeutics, Inc. on May 5, 2022. The companies whose calls Amy Peterson spoke on are classified in the Healthcare sector.
“the employment of Amy Peterson, M.D., the Company's President and Chief Operating Officer, is expected to terminate effective September 12, 2022”
“As mentioned, we continue to focus on execution of our Phase 2 study. And to that end, we have achieved important milestones.”
“I am very excited about the progress we are making at CytomX and look forward to continuing to deliver on our goal of building our company for the long term and making real our promise to positively impact the lives of people with cancer.”
2022-02-02–2022-09-12
Proxy statement
Start not stated–2021-04-28
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2025-04-16
Last confirmed by a filing; no departure on record
Start not stated–2022-09-12
Biotechnology · Healthcare
COO
2022-02-02–2022-09-12
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Exelixis, Inc. (EXEL) | Former Executive Vice President, Medical Affairs, and Chief Medical Officer | $614,496 | $11,146,034 |
| 2024 | Exelixis, Inc. (EXEL) | Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer | $654,337 | $4,446,015 |
| 2023 | Exelixis, Inc. (EXEL) | Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer | $201,846 | $7,378,846 |
| 2021 | CytomX Therapeutics, Inc. (CTMX) | Former President and Chief Operating Officer | $520,605 | $2,252,280 |
| 2020 | CytomX Therapeutics, Inc. (CTMX) | President, Chief Operating Officer | $503,000 | $899,442 |
| 2019 | CytomX Therapeutics, Inc. (CTMX) | President, Chief Operating Officer | $107,955 | $3,395,723 |
| 2018 | CytomX Therapeutics, Inc. (CTMX) | Executive Vice President, Chief Development Officer | — | — |
